ClinicalTrials.gg
RecruitingNCT06989749StimMAPUpdated Oct 7, 2026

Transcranial Direct Current Stimulation and Modulation of Affect and Pain

An interventional study of Anodal tDCS and Cathodal tDCS in We Are Not Studying a Disease or Condition, sponsored by Trustees of Dartmouth College. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Trustees of Dartmouth College · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Sep 2023, registered May 2025).
  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Oct 7, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This double-blind randomized crossover study aims to examine the effects of left primary motor cortex (M1) tDCS on evoked thermal pain perception, pain-related decision making, and placebo effects by manipulated pain and monetary offers accepted by others. The investigators plan to collect data for up to 50 participants who undergo four separate sessions: an initial pain calibration session and three experimental sessions with either anodal, cathodal, or sham tDCS. Each session includes pain testing before and after a single tDCS protocol (either anodal, cathodal, or sham), a pain-monetary decision-making task, and social placebo pain tests. All tasks following tDCS will take place inside the MR scanner. The investigators hypothesize that anodal M1 tDCS will decrease pain ratings, and that cathodal tDCS will increase them, both relative to the sham condition. The investigators will also examine the effects of M1 tDCS on social decision-making to examine whether it affects participants' valuation of pain and their altruistic behavior, as well as how these same factors impact pain sensation in the placebo task. The investigators hypothesize that participants will behave hyperaltruistically during the decision-making task, and that the same factors that influence choice will also impact pain perception in the same context.

Read the detailed description

This study aims to examine the effects of M1 tDCS on induced experimental pain, pain-related decision making, and independently manipulate expectations based on the pain and monetary offered by others. This study involves 4 sessions, one thermal calibration session and three full study sessions where subjects will experience one of three tDCS conditions: anodal, cathodal, or sham. Participants receive only one condition of tDCS for each full session, and the order of which tDCS condition they receive is randomized. Participants are also asked to complete a decision-making task during each full study session, a Single-trial heat stimulation task based on the decision-making task, and finally a Social Decision Making and Placebo Responses task. Participants will complete all tasks following tDCS inside the MR scanner.

The initial pain calibration session is performed as a part of the screening process for each participant to ensure that all temperatures delivered during any subsequent procedures are within participants' tolerable range, and to obtain consent to participate in this research. The calibration procedure can improve the accuracy of the measurement because it adjusts the temperature based on the participants' reported sensation and allows for the determination of an individual's pain and tolerance level. Four runs (6 trials in each run and 24 trials totally) of noxious heat are administered to six forearm sites using iterative adaptive logistic regression. Each stimulus lasts 13 seconds, with 1.5 seconds for ramping. Sensation is rated on a circular scale from "no sensation" to "strongest imaginable". Participants report pain and tolerance with "yes" or "no" responses to "Painful?" and "Tolerate?" questions. The first calibration run familiarizes participants with 47°C heat on all sites. The second run includes 45°C, 47°C, and 48.9°C stimuli twice, randomly distributed. Runs three and four include low and high temperatures based on the pain and tolerance responses of previous trials. A logistic regression based on a 90% response to pain and tolerance of previous trials is used to determine the low and high threshold and is updated after each trial. After the final trial, low (pain) and high (tolerance) temperatures are determined using logistic regression across all trials, and three sites with the least mean absolute error values in rate-temperature linear regression are chosen for pain stimulation.

Each full session includes 3 run pains runs before tDCS, 20 min tDCS, 3 run pains tests after tDCS, Decision making task, and 3 runs of social decision making and placebo responses task. Each full session begins with three pain runs on three different regions of the right forearm (out of the 6 possible regions) used during the initial calibration session, and ends with three more pain runs on these same regions after tDCS. Each pain run consists of 12 trials using each participants' unique temperature range (pain and tolerance) obtained from the calibration session, such that there are 36 trials before tDCS, and 36 trials after tDCS.

The tDCS device is applied at 2 mA for 20 minutes using the StarStim system (Neuroelectrics, Spain). Electrodes are placed on the C3 and FP2 regions. There is a 30-second ramp-up and 30-second ramp-down of stimulation for each tDCS condition to minimize any discomfort during stimulation. During stimulation, a random fractal image is displayed on the participant's computer screen. Originally, the main purpose of presenting a random image during each tDCS stimulation was to facilitate a 1-month follow-up session for a memory test planned for future study. The assignment of pictures to task conditions is randomized for each participant and therefore picture identity is not confounded with task variables. After tDCS, participants complete a questionnaire related to sensations induced by tDCS.

Decision-making task During the initial phase of the decision-making task, participants are presented with 128 trials where they are given the option to either accept or reject offers for pain and monetary reward levels. The pain levels for the offers are randomized from 8 possible levels of each participant's own unique pain tolerance threshold (or 20%-90% of their tolerance), and the monetary rewards are also randomized from $1 to $8. The presentation order of the pain levels and monetary values for each offer are also randomized (e.g., $5 for 60%, or, 20% for $3, etc.). Participants are instructed that each monetary value represents 10 heat stimulation at that percentage of tolerance. The 128 offers are divided into two sets of 64 trials each, where the first set involves decisions about offers for oneself, while the second set involves decisions about offers for others. No heat stimulation is involved while participants complete the first phase of the task, and the trials are presented in blocks of 8 for each type. Upon completing the initial phase of the task, a random selection of trials decided for others are chosen, and the average reward value associated with the accepted trials among these trials is paid to the participants as compensation for their involvement in this task. In addition, one random trial from the decisions participants made for himself/herself is selected, and participants receive either 10 heat stimulation at that percent of tolerance and additional monetary value or no pain/monetary.

Social Decision Making and Placebo Responses Participants are also told during the second phase of this task that they will additionally receive three sets of 12 heat stimulation trials randomly selected from previous participants' decisions for future participants. Participants are first shown the decision from the previous participant (e.g., x. 50% tolerance paired with $4) and then receive a heat stimulation based on that offer. However, unbeknownst to participants, participants either receive a "high" or "low" temperature every trial in which the high temperature is always the participants maximum heat tolerance, and the low temperature is the maximum heat tolerance minus 1 degree celsius.

Full study sessions are scheduled with at least five days in between sessions, and roughly during the same time of day (e.g., morning, afternoon, evening, etc.).

02

Conditions studied

  • We Are Not Studying a Disease or Condition

Keywords

  • transcranial direct current stimulation
  • experimental pain
  • pain-related decision-making
  • social placebo effects
03

In context

Lead sponsor

Trustees of Dartmouth College is the lead sponsor of 38 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ages 18-55
  • Participants must be capable of performing experimental tasks (e.g., are able to read)
  • Fluent or native speakers of English

Exclusion criteria

Exclusion Criteria:

  • No self-reported current or history of depression, bipolar disorder, or other psychiatric diagnosis.
  • No self-reported current seizure disorder (i.e., seizure within past 10 years)
  • No history of stroke or other major neurological diagnosis.
  • No self-reported current chronic pain, or acute pain within three months of the study period.
  • No current migraine disorder (i.e., 15 headache days or more in 1 month).
  • No use of central nervous system-effective medication or other medication for neurological/psychiatric treatment. No self-reported substance abuse within the last six months.
  • No to MRI or tDCS (e.g., pregnancy, claustrophobia, pacemakers, ear/cochlear implants, shrapnel injuries, clips, or other ferromagnetic/electrical objects/devices, diagnosed brain abnormality such as tumor, or skin lesions on the scalp.).
  • No contraindications for induced pain (e.g., no heart disease, high blood pressure, heart surgery, heart problems of any kind, severe asthma, respiratory problems of any kind, fibromyalgia, Raynaud's Syndrome or Disease, chronic pain, diabetes).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Condition 1: Anodal tDCS -> Cathodal tDCS -> Sham tDCS

    Each participant experiences an initial pain calibration session, followed by three full study sessions involving anodal, cathodal, or sham tDCS interventions. Only one intervention type (anodal, cathodal, or sham) is applied per session, in a randomized and double-blind fashion. In this arm anodal is applied session 1, cathodal is applied session 2, and sham is applied session 3.

    Other: Anodal tDCS · Other: Cathodal tDCS · Other: Sham tDCS

  • Other
    Condition 2: Anodal tDCS -> Sham tDCS -> Cathodal tDCS

    Each participant experiences an initial pain calibration session, followed by three full study sessions involving anodal, cathodal, or sham tDCS interventions. Only one intervention type (anodal, cathodal, or sham) is applied per session, in a randomized and double-blind fashion. In this arm anodal is applied session 1, sham is applied session 2, and cathodal is applied session 3.

    Other: Anodal tDCS · Other: Cathodal tDCS · Other: Sham tDCS

  • Other
    Condition 3: Sham tDCS -> Cathodal tDCS -> Anodal tDCS

    Each participant experiences an initial pain calibration session, followed by three full study sessions involving anodal, cathodal, or sham tDCS interventions. Only one intervention type (anodal, cathodal, or sham) is applied per session, in a randomized and double-blind fashion. In this arm sham is applied session 1, cathodal is applied session 2, and anodal is applied session 3.

    Other: Anodal tDCS · Other: Cathodal tDCS · Other: Sham tDCS

  • Other
    Condition 4: Sham tDCS -> Anodal tDCS -> Cathodal tDCS

    Each participant experiences an initial pain calibration session, followed by three full study sessions involving anodal, cathodal, or sham tDCS interventions. Only one intervention type (anodal, cathodal, or sham) is applied per session, in a randomized and double-blind fashion. In this arm sham is applied session 1, anodal is applied session 2, and cathodal is applied session 3.

    Other: Anodal tDCS · Other: Cathodal tDCS · Other: Sham tDCS

  • Other
    Condition 5: Cathodal tDCS -> Sham tDCS -> Anodal tDCS

    Each participant experiences an initial pain calibration session, followed by three full study sessions involving anodal, cathodal, or sham tDCS interventions. Only one intervention type (anodal, cathodal, or sham) is applied per session, in a randomized and double-blind fashion. In this arm cathodal is applied session 1, sham is applied session 2, and anodal is applied session 3.

    Other: Anodal tDCS · Other: Cathodal tDCS · Other: Sham tDCS

  • Other
    Condition 6: Cathodal tDCS -> Anodal tDCS -> Sham tDCS

    Each participant experiences an initial pain calibration session, followed by three full study sessions involving anodal, cathodal, or sham tDCS interventions. Only one intervention type (anodal, cathodal, or sham) is applied per session, in a randomized and double-blind fashion. In this arm cathodal is applied session 1, anodal is applied session 2, and sham is applied session 3.

    Other: Anodal tDCS · Other: Cathodal tDCS · Other: Sham tDCS

Interventions

  • OtherAnodal tDCS

    Transcranial direct current stimulation (tDCS) is an experimental manipulation of brain circuitry using electrical current applied to the scalp. The equipment is commercially available (StarStim8, Neuroelectrics, Spain) and marketed for experimental research on brain function. Current is applied at 2 mA for 20 minutes. Electrodes are placed on the C3 and FP2 regions. There is a 30-second ramp-up and 30-second ramp-down of stimulation for each tDCS condition to minimize any discomfort during stimulation. In the anodal condition, real tDCS stimulation enters from the C3 electrode, and exits at the FP2 electrode.

    Also known as: Anodal Transcranial Direct Current Stimulation

  • OtherCathodal tDCS

    Transcranial direct current stimulation (tDCS) is an experimental manipulation of brain circuitry using electrical current applied to the scalp. The equipment is commercially available (StarStim8, Neuroelectrics, Spain) and marketed for experimental research on brain function. Current is applied at 2 mA for 20 minutes. Electrodes are placed on the C3 and FP2 regions. There is a 30-second ramp-up and 30-second ramp-down of stimulation for each tDCS condition to minimize any discomfort during stimulation. In the cathodal condition, real tDCS stimulation enters from the FP2 electrode, and exits at the C3 electrode.

    Also known as: Cathodal Transcranial Direct Current Stimulation

  • OtherSham tDCS

    This is the sham (or placebo) tDCS intervention. The tDCS device is applied for one minute, for a 30-second ramp-up and 30-second ramp-down of stimulation.

    Also known as: Sham Transcranial Direct Current Stimulation

06

What researchers measure

Primary outcomes

  1. Pain Visual Analogue Scale

    Self-reported pain level following each thermal stimulus, measured on a visual analog scale. 0-100 scale with 0 indicating no pain and higher values indicating more pain.

    Time frame: 3-10 sec post-stimulus throughout testing sessions, on average complete within 1 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Electronic data will be stored indefinitely and will not be shared with other investigators without explicit permission from the overseeing IRB.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Sep 2026 → Nov 2026 and completion Sep 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 25, 2025
StartActual
Sep 9, 2023
Primary completionEst.
Nov 30, 2026was Sep 2026
CompletionEst.
Nov 30, 2026was Sep 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Nov 30, 2026
Oct 7, 2026
Study completion
Sep 2026→Nov 30, 2026
Oct 7, 2026
Interventions
Arms added: Condition 1: Anodal tDCS -> Cathodal tDCS -> Sham tDCS·Condition 2: Anodal tDCS -> Sham tDCS -> Cathodal tDCS·Condition 3: Sham tDCS -> Cathodal tDCS -> Anodal tDCS·Condition 4: Sham tDCS -> Anodal tDCS -> Cathodal tDCS·Condition 5: Cathodal tDCS -> Sham tDCS -> Anodal tDCS·and 1 more
All 6

Condition 1: Anodal tDCS -> Cathodal tDCS -> Sham tDCS · Condition 2: Anodal tDCS -> Sham tDCS -> Cathodal tDCS · Condition 3: Sham tDCS -> Cathodal tDCS -> Anodal tDCS · Condition 4: Sham tDCS -> Anodal tDCS -> Cathodal tDCS · Condition 5: Cathodal tDCS -> Sham tDCS -> Anodal tDCS · Condition 6: Cathodal tDCS -> Anodal tDCS -> Sham tDCS

; arms removed: Within-person Crossover
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Primary completion Sep 2026→Nov 30, 2026
    Study completion Sep 2026→Nov 30, 2026
    Interventions Arms added: Condition 1: Anodal tDCS -> Cathodal tDCS -> Sham tDCS·Condition 2: Anodal tDCS -> Sham tDCS -> Cathodal tDCS·Condition 3: Sham tDCS -> Cathodal tDCS -> Anodal tDCS·Condition 4: Sham tDCS -> Anodal tDCS -> Cathodal tDCS·Condition 5: Cathodal tDCS -> Sham tDCS -> Anodal tDCS·and 1 more
    All 6

    Condition 1: Anodal tDCS -> Cathodal tDCS -> Sham tDCS · Condition 2: Anodal tDCS -> Sham tDCS -> Cathodal tDCS · Condition 3: Sham tDCS -> Cathodal tDCS -> Anodal tDCS · Condition 4: Sham tDCS -> Anodal tDCS -> Cathodal tDCS · Condition 5: Cathodal tDCS -> Sham tDCS -> Anodal tDCS · Condition 6: Cathodal tDCS -> Anodal tDCS -> Sham tDCS

    ; arms removed: Within-person Crossover
    + 3 other changes: index terms, verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06989749
Lead sponsor
Trustees of Dartmouth College
Responsible party
Tor Wager (Diana L. Taylor Distinguished Professor, Trustees of Dartmouth College) — Principal investigator
First posted
May 25, 2025
Start date
Sep 9, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 7, 2026

Study contacts

Tor Wager D Principal Investigator, PhD
Contact
Tor.D.Wager@Dartmouth.edu
603-646-2196

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion